October 14, 2019

DHVI Plays Integral Role in National Effort to Improve Flu Shots

DURHAM, N.C. -- DHVI’s contracts potentially totaling $400 million are the largest in a federal drive to modernize flu vaccines. As part of a massive national effort to improve and modernize flu shots, the Duke Human Vaccine Institute has received three research contracts from the National Institute of Allergy and Infectious Diseases (NIAID), with an initial award of approximately $29.6 million in first-year funding.  Duke is the only institution to receive a contract in each of the three CIVICs components, including work to the design and evaluate influenza vaccine approaches, manufacture and evaluate the safety and toxicity of vaccine platforms, and conduct clinical trials for influenza vaccines.